Loading…
Loading…
JCO (Nuveen Credit Opportunities 2022 Target Term Fund) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
American Community Newspapers (OTCMKTS:ACNI - Get Free Report) and Daily Journal Corp. (S.C.) (NASDAQ: DJCO - Get Free Report) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability. Valuation and Earnings This
Data Support Clinical Performance of Galleri to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology.
SAN FRANCISCO and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1
NEW YORK--(BUSINESS WIRE)--The Nuveen Credit Opportunities 2022 Target Term Fund (NYSE: JCO) completed its termination and liquidation following the close of business on June 1, 2022. The termination and liquidation was performed in accordance with the fund’s investment objectives and organizational documents, consistent with the fund’s previously announced liquidation plans. The Nuveen Credit Opportunities 2022 Target Term Fund launched on March 28, 2017 as a short duration strategy that invested primarily in high yield corporate debt, with two investment objectives, to provide high current income and to return the original net asset value (Original NAV) of $9.85 per common share upon termination on or about June 1, 2022. As anticipated, due to market conditions, JCO did not return the Original NAV at its termination. The investment objective relating to Original NAV was not a guarantee and was dependent on a number of factors including the extent of market recovery and the cumulative level of income retained in relation to cumulative portfolio gains net of losses. The fund is returning to shareholders an extended NAV of $7.9446 per common share as its liquidating distribution. Investors should consider the distribution announced today along with the previously announced special distribution declared on May 12, 2022 as part of the final distribution of proceeds in connection with the fund’s investment objective. The fund’s final liquidating distribution amount is listed below. Per share details are as follows: Special distribution declared on May 12, 2022 $0.0713 Final liquidating distribution announced today $7.9446 Total distribution $8.0159 Over its five year term, the fund paid 60 regular distributions totaling $2.6770 per share, which equates to an average distribution rate of 5.25% on NAV and 5.17% on market price. The annualized total return on NAV for shareholders who invested at the initial public offering was 1.77% and the total return on market price was 1.54%. Shareholders may recognize a gain or loss for U.S. tax purposes as a result of the liquidation. Nuveen does not provide tax advice; investors should consult a professional tax advisor regarding their specific tax situation. Nuveen is a leading sponsor of closed-end funds (CEFs) with $62 billion of assets under management across 58 CEFs as of 31 Mar 2022. The funds offer exposure to a broad range of asset classes and are designed for income-focused investors seeking regular distributions. Nuveen has more than 30 years of experience managing CEFs. For more information, please visit Nuveen’s CEF homepage www.nuveen.com/closed-end-funds or contact: Financial Professionals: 800-752-8700 Investors: 800-257-8787 Media: media-inquiries@nuveen.com About Nuveen Nuveen, the investment manager of TIAA, offers a comprehensive range of outcome-focused investment solutions designed to secure the long-term financial goals of institutional and individual investors. Nuveen has $1.2 trillion in assets under management as of 31 Mar 2022 and operations in 27 countries. Its investment specialists offer deep expertise across a comprehensive range of traditional and alternative investments through a wide array of vehicles and customized strategies. For more information, please visit www.nuveen.com. Nuveen Securities, LLC, member FINRA and SIPC. The information contained on the Nuveen website is not a part of this press release. FORWARD-LOOKING STATEMENTS Certain statements made or referenced in this release may be forward-looking statements. Actual future results or occurrences may differ significantly from those anticipated in any forward-looking statements due to numerous factors. These include, but are not limited to: market developments, including the timing of distributions and other events identified in this press release; legal and regulatory developments; and other additional risks and uncertainties. EPS-2223962PR-E0622X
NEW YORK--(BUSINESS WIRE)--Nuveen today announced that the Nuveen Credit Opportunities 2022 Target Term Fund (NYSE: JCO) declared a special income distribution. The following dates apply to today’s special distribution declaration: Record Date May 25, 2022 Ex-Dividend Date May 24, 2022 Payable Date May 31, 2022 Ticker Exchange Fund Name Special Per Share Income Distribution JCO NYSE Nuveen Credit Opportunities 2022 Target Term Fund $0.0713 As previously announced, consistent with its investment objectives and organizational documents, the fund plans to terminate its existence and liquidate on or about June 1, 2022. As the fund approaches liquidation, its common shares will continue trading on the New York Stock Exchange through May 25, 2022 and will be suspended from trading before the open of trading on May 26, 2022. The current net asset value (NAV) of the fund as of the close of business on May 11, 2022 was $8.03. The fund’s NAV will be reduced by the amount of the distribution declared today on the Ex-Dividend Date. The special distribution declared today, together with the fund’s final liquidating distribution, should be considered as part of the fund’s objective to return the original $9.85 net asset value of the fund (Original NAV) on or about June 1, 2022. As previously announced, due to market conditions, JCO does not anticipate returning the Original NAV at its termination. The investment objective relating to Original NAV is not a guarantee and is dependent on a number of factors including the extent of market recovery and the cumulative level of income retained in relation to cumulative portfolio gains net of losses. Nuveen is a leading sponsor of closed-end funds (CEFs) with $62 billion of assets under management across 58 CEFs as of 31 Mar 2022. The funds offer exposure to a broad range of asset classes and are designed for income-focused investors seeking regular distributions. Nuveen has more than 30 years of experience managing CEFs. For more information, please visit Nuveen’s CEF homepage www.nuveen.com/closed-end-funds or contact: Financial Professionals: 800-752-8700 Investors: 800-257-8787 Media: media-inquiries@nuveen.com About Nuveen Nuveen, the investment manager of TIAA, offers a comprehensive range of outcome-focused investment solutions designed to secure the long-term financial goals of institutional and individual investors. Nuveen has $1.2 trillion in assets under management as of 31 Mar 2022 and operations in 27 countries. Its investment specialists offer deep expertise across a comprehensive range of traditional and alternative investments through a wide array of vehicles and customized strategies. For more information, please visit www.nuveen.com. Nuveen Securities, LLC, member FINRA and SIPC. The information contained on the Nuveen website is not a part of this press release. FORWARD-LOOKING STATEMENTS Certain statements made or referenced in this release may be forward-looking statements. Actual future results or occurrences may differ significantly from those anticipated in any forward-looking statements due to numerous factors. These include, but are not limited to: market developments, including the timing of distributions and other events identified in this press release; legal and regulatory developments; and other additional risks and uncertainties. EPS-2188775PR-E0522X
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for JCO and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.